financial guidance
Pfizer Oncology Product Revenues Jump 26 Percent in Q2
The firm reported $845 million in Q2 revenue from oncology products gained in its acquisition of Seagen last year.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.
May 2, 2023
Feb 3, 2023
Feb 1, 2023
Apr 29, 2022
Gilead Sciences More Than Doubles Q1 Trodelvy Sales
Oct 30, 2019
Apr 30, 2019